ClinicalTrials.gg
CompletedNCT07086235Updated Nov 26, 2025

Remineralization Capacity and Patient Satisfaction of Self-Assembling Peptide With Fluoride Versus Tooth Protective Coating With Surface Pre-Reacted Glass on White Spot Lesions

An interventional study of self-assembling peptide and S-PRG Barrier Coat in White Spot Lesions, sponsored by Nahda University. Completed at 1 site in Egypt. Open to participants aged 21 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Nahda University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2025, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
21 Years to 25 Years
Sex
All
01

Study summary

Cosmetics and esthetics are current trends of our society, as more and more patients are demanding for minimally invasive cosmetic enhancement without anesthesia, drilling and less expensive restorations. This technique may be considered as micro invasive treatment of smooth surface white spot lesions (WSL) and also one that allows for the recovery of natural tooth appearance. Dentists are frequently faced with the treatment of color aberrations of teeth, as WSL which is caused by demineralization of enamel, and labial white spots are frequently associated with fixed orthodontic treatment. Clinically, the appearance of the lesion is opaque white, due to the optical phenomenon caused by mineral loss and the difference in the refractive index of water and air that fill the spaces formed in the enamel. The milky color of WSL impairs dramatically the esthetic appearance thus reducing satisfaction of orthodontic therapy, making their treatment become nowadays mandatory. Regarding the diagnosis, it is essential that the dentist does not lose the ability to detect a carious lesion or a WSL through visual or photographic examination, as is the most conventional way. However, other forms of diagnosis have emerged, such as fluorescence devices, as well as microradiography and microcomputed tomography to facilitate and accelerate the diagnostic process.

Conventionally, topical fluoride application has been used to manage WSLs in which the structure of the tooth is altered due to fluorapatite, thus becoming more resistant to caries. However, this approach has the disadvantage of depending on patient compliance and its results can be disappointing when solely used in high-risk patients. A recent biomimetic material has been introduced to dental market, namely, Curodont Repair Fluoride Plus, which is regarded as a possible substitute to fluoride to arrest WSL progression with the aim of filling the intercrystalline spaces for enamel subsurface lesions through a self-assembling peptide that builds a supramolecular three-dimensional, fibrous network in the acidic environment attracts calcium phosphate from saliva and produced de novo hydroxyapatite crystals surrounding the matrix with containing fluoride which have synergistic effect and enhance faster remineralization in management of WSLs. Another recent generation of patented bioactive smart remineralizing material, S-PRG Barrier Coat has been launched to remineralize WSLs where S-PRG pretreated fluoro-boro-aluminosilicate glass with polyacrylic acid and water to recharge and release fluoride. Additionally, releasing more types of ions this aid in biofilm suppression, decrease adhesion of bacteria, buffering capacity of acids, and enhances remineralization. The aim of this study is to compare the remineralization capacity and patient satisfaction of self-assembling peptide with fluoride versus tooth protective coating with surface pre-reacted glass on white spot lesions.

02

Conditions studied

  • White Spot Lesions
03

In context

Lead sponsor

Nahda University is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- No systemic diseases. 2- He/ she has at least two teeth with white spot lesion due to orthodontic therapy.

3- Between the ages of 21 and 25 years of age.

Exclusion criteria

Exclusion criteria:

  1. Presence of enamel hypoplasia or dental fluorosis.
  2. Presence of tetracycline pigmentation.
  3. Periodontal pocketing of 3 mm or greater.
  4. Presencia de cavidades cariosas.
  5. Allergy to fluoride.
  6. Subjects who have evidence of reduced salivary flow or significant tooth wear.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Curodont Repair Fluoride Plus

    Drug: self-assembling peptide

  • Experimental
    S-PRG Barrier Coat

    Drug: S-PRG Barrier Coat

Interventions

  • Drugself-assembling peptide

    According to the instructions of the manufacturer, the lesion will be treated with etch solution (Super Etch, SDI Ltd, Bayswater, Victoria, Australia) for 30 seconds to open up the pores to the subsurface lesion and subsequently will be washed and dried. Curodont Repair Fluoride Plus brush will be rehydrated with 0.05 ml of sterile water and a single drop of the resulting solution will be immediately applied to the lesion surface. Moisture control will be ensured until the Curodont Repair Fluoride Plus solution will be no longer visible (approximately two minutes).

  • DrugS-PRG Barrier Coat

    According to the instructions of the manufacturer, after mixing one drop of activator with base, a thin film coating will be applied to the WSL area then will be left undistributed for 3 seconds and finally will be light cured for 10 seconds using LED light-curing unit.

06

What researchers measure

Primary outcomes

  1. Color change assessment

    Spectrophotometric color measurements will be performed using Vita Easy Shade (VITA Zahnfabrik, Germany). Only the lightness difference (ΔL\*) value between baseline and after treatment will be recorded in this study.

    Time frame: Base-line (before treatment), immediately after treatment, 1-month, 3-month, and 6-months.

Secondary outcomes

  1. Depth of White Spot Lesions

    The depth of all lesions from all subjects will be assessed using DIAGNOdent (KaVo, Germany), which relies on measuring the amount of fluorescence released by organic substances in dental tissues when stimulated by a 655 nm laser diode.

    Time frame: Base-line (before treatment), immediately after treatment, 1-month, 3-months, and 6-months.

Other outcomes

  1. Patient satisfaction

    Patient satisfaction will be assessed using the visual Analog Scale Score (VAS). The VAS is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points. A 10 cm line with the anchor words "no sensitivity" at one end and "intolerable sensitivity" at the other end.

    Time frame: Base-line (before treatment), immediately after treatment, 1-month, 3-months, and 6-months.

07

Study locations

1 site
  • Nahda University
    Banī Suwayf, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Aug 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 25, 2025
StartActual
Feb 16, 2025
Primary completionActual
Aug 16, 2025
CompletionActual
Aug 16, 2025
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07086235
Lead sponsor
Nahda University
Responsible party
Khaled Wagih Al-Saudi (Lecturer of Operative and Conservative Dentistry, Nahda University) — Principal investigator
First posted
Jul 25, 2025
Start date
Feb 16, 2025
Primary completion
Aug 16, 2025
Completion
Aug 16, 2025
Last update
Nov 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion